Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display

Circulation

Volumn 102, Issue 2, 2000, Pages 231-237

  Nicklin, Stuart A ^b   White, Steve J ^b   Watkins, Sarah J ^b   Hawkins, Robert E ^b   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

Bacteriophages; Cells; Gene therapy; Peptides; Viruses

Indexed keywords

PEPTIDE;

ADENOVIRUS; ARTICLE; BACTERIOPHAGE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE TARGETING; HUMAN; HUMAN CELL; PHAGE DISPLAY; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0034636793     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.2.231     Document Type: Article

References (33)

1. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
2. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B Coxsackieviruses. Proc Natl Acad Sci U S A. 1997;94:3352-3356.
3. Merrick AF, Shewring LD, Sawyer GJ, et al. Comparison of adenovirus gene transfer to vascular endothelial cells in cell culture, organ culture, and in vivo. Transplantation. 1996;62:1085-1089.
4. 99mTc-labeled adenovirus knob (serotype 5). Gene Ther. 1998;5: 798-808.
5. Wickham TJ, Roelvink PW, Brough DE, et al. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol. 1996;14:1570-1573.
6. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol. 1996;70:6831-6838.
7. Wickham TJ, Lee GM, Titus JA, et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 1997;71:7663-7669.
8. Wickham TJ, Tzeng E, Shears LL II, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 1997;71:8221-8229.
9. Krasnykh V, Dmitriev I, Mikheeva G, et al. Characterisation of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol. 1998;72:1844-1852.
10. Vigne E, Mahfouz I, Dedieu J-F, et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol. 1999;73:5156-5161.
11. Harari OA, Wickham TJ, Stocker CJ, et al. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther. 1999;6:801-807.
12. Rogers BE, Douglas JT, Sosnowski BA, et al. Enhanced in vivo gene delivery to human ovarian cancer xenografts utilising a tropism-modified adenovirus vector. Tumor Targeting. 1998;1:25-31.
13. Goldman CK, Rogers BE, Douglas JT, et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 1997;57:1447-1451.
14. Jaffe EA. Culture of human endothelial cells derived from umbilical vein: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
15. Southgate K, Newby AC. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis. 1990;82:113-123.
16. Watkins SJ, Mesyanzhinov V, Kurochkina LP, et al. The adenobody approach to viral targeting: specific and enhanced adenoviral delivery. Gene Ther. 1997;4:1004-1012.
17. Wilkinson GWG, Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 1992;20:2233-2239.
18. Cwirla SE, Peters EA, Barrett RW, et al. Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci U S A. 1990;87:6378-6382.
19. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J Cell Biol. 1994; 124:373-380.
20. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med. 1996;2:299-305.
21. Palmer DB, George AJT, Ritter MA. Selection of antibodies to cell surface determinants on mouse thymic epithelial cells using a phage display library. Immunology. 1997;91:473-478.
22. Szardenings M, Tornroth S, Mutulis F, et al. Phage display on whole cells yields a peptide specific for melanocortin receptor 1. J Biol Chem. 1997;272:27943-27948.
23. Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem. 1999;274:11593-11598.
24. Douglas JT, Rogers BE, Rosenfeld ME, et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 1996;14: 1574-1578.
25. Cheresh D, Spiro R. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human-melanoma cell attachment to vitronectin, fibrinogen and von Willebrand factor. J Biol Chem. 1987; 262:17703-17711.
26. v integrins. In: Takeda Y, ed. Integrins: The Biological Problems. Boca Raton, Fla: CRC Press; 1994:83-99.
27. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380:364-367.
28. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15: 542-546.
29. Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest. 1998;102:430-437.
30. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279: 377-380.
31. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 1995;2:750-756.
32. Hart S, Arancibia-Carcamo C, Wolfert M, et al. Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector. Hum Gene Ther. 1998;9:575-585.
33. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med. 1999;5: 1052-1056.